Paulitschke V - Search Results

1

Proteomics-based insights into mitogen-activated protein kinase inhibitor resistance of cerebral melanoma metastases.

Zila N, Bileck A, Muqaku B, Janker L, Eichhoff OM, Cheng PF, Dummer R, Levesque MP, Gerner C, Paulitschke V. Zila N, et al. Among authors: paulitschke v. Clin Proteomics. 2018 Mar 9;15:13. doi: 10.1186/s12014-018-9189-x. eCollection 2018. Clin Proteomics. 2018. PMID: 29541007 Free PMC article.

2

Entering a new era of rational biomarker discovery for early detection of melanoma metastases: secretome analysis of associated stroma cells.

Paulitschke V, Kunstfeld R, Mohr T, Slany A, Micksche M, Drach J, Zielinski C, Pehamberger H, Gerner C. Paulitschke V, et al. J Proteome Res. 2009 May;8(5):2501-10. doi: 10.1021/pr8010827. J Proteome Res. 2009. PMID: 19222175

3

Introducing the CPL/MUW proteome database: interpretation of human liver and liver cancer proteome profiles by referring to isolated primary cells.

Wimmer H, Gundacker NC, Griss J, Haudek VJ, Stättner S, Mohr T, Zwickl H, Paulitschke V, Baron DM, Trittner W, Kubicek M, Bayer E, Slany A, Gerner C. Wimmer H, et al. Among authors: paulitschke v. Electrophoresis. 2009 Jun;30(12):2076-89. doi: 10.1002/elps.200900072. Electrophoresis. 2009. PMID: 19582709

4

3,3',4,4',5,5'-hexahydroxystilbene impairs melanoma progression in a metastatic mouse model.

Paulitschke V, Schicher N, Szekeres T, Jäger W, Elbling L, Riemer AB, Scheiner O, Trimurtulu G, Venkateswarlu S, Mikula M, Swoboda A, Fiebiger E, Gerner C, Pehamberger H, Kunstfeld R. Paulitschke V, et al. J Invest Dermatol. 2010 Jun;130(6):1668-79. doi: 10.1038/jid.2009.376. Epub 2009 Dec 3. J Invest Dermatol. 2010. PMID: 19956188 Free article.

5

Proteome signatures of inflammatory activated primary human peripheral blood mononuclear cells.

Haudek-Prinz VJ, Klepeisz P, Slany A, Griss J, Meshcheryakova A, Paulitschke V, Mitulovic G, Stöckl J, Gerner C. Haudek-Prinz VJ, et al. Among authors: paulitschke v. J Proteomics. 2012 Dec 5;76 Spec No.(5):150-62. doi: 10.1016/j.jprot.2012.07.012. Epub 2012 Jul 16. J Proteomics. 2012. PMID: 22813876 Free PMC article. Clinical Trial.

6

Proteome analysis identified the PPARγ ligand 15d-PGJ2 as a novel drug inhibiting melanoma progression and interfering with tumor-stroma interaction.

Paulitschke V, Gruber S, Hofstätter E, Haudek-Prinz V, Klepeisz P, Schicher N, Jonak C, Petzelbauer P, Pehamberger H, Gerner C, Kunstfeld R. Paulitschke V, et al. PLoS One. 2012;7(9):e46103. doi: 10.1371/journal.pone.0046103. Epub 2012 Sep 25. PLoS One. 2012. PMID: 23049949 Free PMC article.

7

Functional classification of cellular proteome profiles support the identification of drug resistance signatures in melanoma cells.

Paulitschke V, Haudek-Prinz V, Griss J, Berger W, Mohr T, Pehamberger H, Kunstfeld R, Gerner C. Paulitschke V, et al. J Proteome Res. 2013 Jul 5;12(7):3264-76. doi: 10.1021/pr400124w. Epub 2013 Jun 19. J Proteome Res. 2013. PMID: 23713901 Free PMC article.

8

Determination of cell type-specific proteome signatures of primary human leukocytes, endothelial cells, keratinocytes, hepatocytes, fibroblasts and melanocytes by comparative proteome profiling.

Slany A, Paulitschke V, Haudek-Prinz V, Meshcheryakova A, Gerner C. Slany A, et al. Among authors: paulitschke v. Electrophoresis. 2014 May;35(10):1428-38. doi: 10.1002/elps.201300581. Epub 2014 Mar 20. Electrophoresis. 2014. PMID: 24644141

9

Proteome profiling of keratinocytes transforming to malignancy.

Paulitschke V, Gerner C, Hofstätter E, Mohr T, Mayer RL, Pehamberger H, Kunstfeld R. Paulitschke V, et al. Electrophoresis. 2015 Feb;36(4):564-76. doi: 10.1002/elps.201400309. Epub 2015 Jan 28. Electrophoresis. 2015. PMID: 25395074

10

Vemurafenib resistance signature by proteome analysis offers new strategies and rational therapeutic concepts.

Paulitschke V, Berger W, Paulitschke P, Hofstätter E, Knapp B, Dingelmaier-Hovorka R, Födinger D, Jäger W, Szekeres T, Meshcheryakova A, Bileck A, Pirker C, Pehamberger H, Gerner C, Kunstfeld R. Paulitschke V, et al. Among authors: paulitschke p. Mol Cancer Ther. 2015 Mar;14(3):757-68. doi: 10.1158/1535-7163.MCT-14-0701. Epub 2015 Jan 22. Mol Cancer Ther. 2015. PMID: 25612618

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

31 results

Search Page